Dicerna Pharmaceuticals Inc  

(Public, NASDAQ:DRNA)   Watch this stock  
Find more results for DRNA
10.63
+0.57 (5.67%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.01 - 10.75
52 week 2.52 - 11.19
Open 10.11
Vol / Avg. 0.00/389,408.00
Mkt cap 548.95M
P/E     -
Div/yield     -
EPS -3.43
Shares 51.64M
Beta 2.75
Inst. own 103%
Mar 28, 2018
Q4 2017 Dicerna Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 12, 2018
Dicerna Pharmaceuticals Inc at Cowen Health care Conference - 2:50PM EDT - Add to calendar
Feb 14, 2018
Dicerna Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference
Feb 13, 2018
Dicerna Pharmaceuticals Inc at SunTrust Robinson Humphrey Orphan Drug Day
Jan 30, 2018
Dicerna Pharmaceuticals Inc at Noble Capital Markets Institutional Investor Conference
Nov 30, 2017
Dicerna Pharmaceuticals Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -3171.52% -20173.90%
Operating margin -3209.28% -20253.56%
EBITD margin - -19968.81%
Return on average assets -67.96% -78.68%
Return on average equity -1618.43% -90.01%
Employees 47 -
CDP Score - -

Address

87 Cambridgepark Dr
CAMBRIDGE, MA 02140-2311
United States - Map
+1-617-6218097 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).

Officers and directors

David M. Madden Ph.D. Independent Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Douglas M. Fambrough Ph.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
John B. Green Chief Financial Officer, Principal Financial Officer
Age: 62
Bio & Compensation  - Reuters
Bob D. Brown Ph.D. Senior Vice President, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Theodore T. Ashburn M.D., Ph.D. Senior Vice President - Product Strategy & Operations
Age: 47
Bio & Compensation  - Reuters
Pankaj Bhargava M.D. Chief Medical Officer
Age: 46
Bio & Compensation  - Reuters
Ralf H. Rosskamp M.D. Chief Medical Officer
Age: 63
Bio & Compensation  - Reuters
James B. Weissman Chief Business Officer
Age: 53
Bio & Compensation  - Reuters
Martin I Freed M.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
Brian K. Halak Ph.D. Independent Director
Age: 45
Bio & Compensation  - Reuters